Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuronetics ( (STIM) ) just unveiled an update.
On March 2, 2026, Neuronetics, Inc. and Madryn Asset Management LP executed a second amendment to their Registration Rights Agreement related to shares issued to the Madryn Parties under Neuronetics’ earlier arrangement with Greenbrook TMS Inc., originally disclosed in August and amended in November 2024. The Second Amendment commits Neuronetics, upon receiving a shelf notice, to file a resale registration statement for all Madryn-held registrable securities within five business days after filing its 2025 Form 10-K, while Madryn agrees to vote all its Neuronetics shares in line with the board’s recommendations on specified proposals at the company’s 2026 annual meeting, signaling tighter alignment between a key shareholder and the company’s governance plans.
The most recent analyst rating on (STIM) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
The score is held down primarily by weak financial durability (large losses, negative cash flow, and higher leverage) and bearish technicals (price below major moving averages with negative MACD). The latest earnings call provides some offset via strong reported revenue growth and improving cash burn with a near-term breakeven cash flow target, but margin pressure and reduced guidance keep the outlook cautious.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc. operates in the medical technology sector, focusing on neuromodulation treatments for psychiatric and neurological disorders. The company’s primary products are non-invasive transcranial magnetic stimulation systems, with a market focus on treating major depressive disorder and related mental health conditions through clinical providers.
Average Trading Volume: 1,876,504
Technical Sentiment Signal: Sell
Current Market Cap: $91.77M
For a thorough assessment of STIM stock, go to TipRanks’ Stock Analysis page.